Loading…
Develops alpha-emitting radiopharmaceutical (radioligand) therapies that deliver targeted radiation directly to tumors.
Develops alpha-emitting radiopharmaceutical (radioligand) therapies that deliver targeted radiation directly to tumors.
Has no product on sale and earns nothing from customers, so development is funded by money raised from investors and potentially partners. Its value rests on clinical results for one family of cancer drugs.
Moat: narrow (IP / patents, process know-how). Radiopharmaceutical manufacturing and isotope supply-chain know-how are hard for new entrants to build.
Headquarters: Boston, Massachusetts, US · Founded: 2019 · Employees: 79
Size Aktis Oncology (AKTS) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $880M, the 2327th largest of 3,117 United States companies the cockpit tracks. Shares closed at $15.82 on 6 Nov 2026.
Performance Over six months the shares fell 14.9%, against -11.9% for the median peer and -1.1% for the United States market (cap-weighted) — 10th lowest of 20 in its peer set.
Growth Revenue grew 336.9% over the last twelve months (peer median +1.6%); the operating margin is -1,149.5% (peer median 8.9%).
Valuation It trades at 57.5× enterprise value to sales against a peer median of 4.3× (most expensive of 18).
Short interest Short interest is 8.0% of the free float (15 Oct 2026).
Next results Next results expected around 2 Dec 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Revenue | n/a | $6.50M | $1.49M | $0 |
| Revenue growth | — | +337% | — | — |
| Gross profit | n/a | $4.17M | -$88,000 | -$1.12M |
| EBITDA | n/a | -$72.4M | -$50.5M | -$33.7M |
| Net income | n/a | -$63.7M | -$44.0M | -$28.6M |
| Free cash flow | n/a | -$73.7M | $11.9M | -$33.8M |
| Capital expenditure | n/a | $9.58M | $2.86M | $3.76M |
| Total debt | $11.2M | $11.5M | $12.0M | $13.4M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Aktis Oncology AKTS | $880M | -15% | +337% | -1,150% | 57.5× | n/a |
| Novartis NOVN.SW | $298B | +15% | -4% | 30% | 6.3× | 1.7% |
| AstraZeneca AZN.L | $291B | +1% | +5% | 23% | 5.1× | 14.5% |
| Bristol Myers Squibb BMY | $127B | +12% | +4% | 33% | 3.2× | -12.9% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | AKTS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -10.8% | -6.5% | 6th lowest of 21 |
| 6-month return | -14.9% | -11.9% | 10th lowest of 20 |
| Distance from 52-week high | -53.7% | -36.0% | 3rd lowest of 21 |
| Revenue growth (TTM) | +336.9% | +1.6% | highest of 18 |
| Operating margin | -1,149.5% | 8.9% | lowest of 18 |
| EV / Sales | 57.5× | 4.3× | most expensive of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Aktis Oncology AKTS | United States | $880M | -15% | +337% | -1,150% | 57.5× | n/a | n/a |
| Daewoong Pharm 069620.KS | South Korea | $874M | -30% | +9% | 12% | 0.7× | n/a | n/a |
| Pharming PHARM.AS | Netherlands | $874M | -2% | +2% | 9% | 2.1× | 2.5% | +12.4% |
| Corvus Pharmaceuticals CRVS | United States | $887M | -32% | n/a | n/a | n/a | n/a | n/a |
| Aarti Pharmalabs AARTIPHARM.NS | India | $892M | +19% | +13% | 18% | 4.3× | n/a | n/a |
| Zhejiang Ausun Pharmaceutical 603229.SS | China | $893M | -27% | +1% | 0% | 7.1× | n/a | n/a |
| Beijing Sun-Novo Pharmaceutical Research 688621.SS | China | $894M | -8% | -1% | -2% | 6.1× | n/a | n/a |
| Hygeia Healthcare 6078.HK | Hong Kong | $861M | -7% | +2% | 14% | 1.9× | 4.8% | +22.5% |
| Kaken Pharmaceutical 4521.T | Japan | $854M | -8% | -7% | 11% | 0.9× | n/a | n/a |
| Guizhou Bailing Group Pharmaceutical 002424.SZ | China | $907M | -12% | -25% | 2% | 2.9× | 16.2% | -0.2% |
| Wanbangde Pharmaceutical 002082.SZ | China | $909M | -65% | -11% | -3% | 5.9× | -1.2% | -39.5% |
| Hunan Er-Kang Pharmaceutical 300267.SZ | China | $909M | -33% | -14% | -29% | 5.2× | n/a | n/a |
| Bide Pharmatech 688073.SS | China | $912M | +5% | +10% | 19% | 3.6× | 16.7% | +27.7% |
| Oric Pharmaceuticals ORIC | United States | $914M | 0% | n/a | n/a | n/a | n/a | n/a |
| Luye Pharma 2186.HK | Hong Kong | $839M | -36% | +3% | 18% | 1.2× | -10.5% | +1.9% |
| Latigo Biotherapeutics LTGO | United States | $835M | n/a | n/a | n/a | n/a | n/a | n/a |
| Sanofi Consumer Healthcare India SANOFICONR.NS | India | $835M | -28% | +23% | 36% | 8.1× | 17.1% | +22.7% |
| Dezhan Healthcare 000813.SZ | China | $928M | -18% | -10% | -121% | 15.8× | n/a | n/a |
| GuangYuYuan Chinese Herbal Medicine 600771.SS | China | $930M | -24% | -6% | 5% | 4.4× | 33.2% | +4.2% |
| Nxera Pharma 4565.T | Japan | $932M | +63% | +24% | 14% | 5.1× | 16.2% | +27.3% |
| Zhejiang Int'l 000411.SZ | China | $828M | -8% | +3% | 3% | 0.3× | n/a | n/a |